About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Leukemia and Lymphoma
›
Top Articles
Leukemia and Lymphoma
Hematology
,
Oncology
1.9
(top 9%)
Impact Factor
2.1
(top 9%)
extended IF
97
(top 4%)
H-Index
6.3K
authors
12.7K
papers
166.5K
citations
5.8K
citing journals
56.6K
citing authors
Most Cited Articles of Leukemia and Lymphoma
Title
Year
Citations
Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F
2001
247
Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management
2000
238
CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy
1995
226
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China
2002
225
18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT
2000
222
Management of adverse events associated with idelalisib treatment: expert panel opinion
2015
221
Rituximab-related viral infections in lymphoma patients
2007
209
Granulocytic sarcoma: 32 cases and review of the literature
2006
200
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
2008
199
Preclinical versus clinical drug combination studies
2008
187
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2013
177
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
2003
177
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
2008
174
Improved outcome of zygomycosis in patients with hematological diseases?
2004
171
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
2011
168
Mastocytosis: pathology, genetics, and current options for therapy
2005
165
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia
2002
163
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)
2004
161
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel
2011
160
Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
2017
157
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance
2007
153
L-asparaginase and PEG asparaginase--past, present, and future
1993
152
Epidemiology of myeloproliferative neoplasms in the United States
2014
149
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
2008
146
Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
1993
146
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.